Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China - Top-Institutions - MDSpire

Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China

  • By

  • Chaoyan He

  • Rongjin Zhang

  • Hua Zhang

  • Shudong Zhang

  • Shumin Wang

  • February 3, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Urologic Oncology
    • Vascular Surgery
    • Robotic Surgery

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Surgical Oncology
    • Minimally Invasive Surgery

  • #3

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Urologic Oncology
    • Vascular Surgery
    • Translational Research

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Urologic Oncology
    • Vascular Surgery
    • Robotic Surgery

  • #5

    Peking University First Hospital
    Peking University First Hospital

    Beijing, China

    Key Differentiators

    • Urologic Oncology
    • Vascular Surgery
    • Clinical Research

Original Source(s)

Impact of Azygos Venous Pathway Status on Surgical Difficulty in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus: A Retrospective Study with a Large Cohort from China

  • by Chaoyan He, Rongjin Zhang, Hua Zhang, Shudong Zhang, Shumin Wang

  • February 3, 2026

Related Content

Correction: Study on the mechanism of 18β-glycyrrhetinic acid inhibiting the proliferation of renal cancer cells by inducing autophagy through the miR-27a-5p/LC3 axis

DNER drives glycolytic reprogramming in renal cell carcinoma by activating the JAK2/STAT3 signaling pathway

Robotic vs. open partial cytoreductive nephrectomy in metastatic renal cell carcinoma: adverse in-hospital outcomes